楷莱在淋巴瘤领域的必威体育精装版进展.pptVIP

* Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: XBCA0193-08325-31 Tulpule – 基线特征 组织学分型 - 弥漫大细胞淋巴瘤 - 高危（高分级） - 滤泡型 分级(III/IV) IPI 评分 – 高危或中危 n 27 4 4 2/27 23 Tulpule et al. Proc Am Soc Clin Oncol 2005 (abst 6634) 屡烷道冰戏啼样部苹概男怔敖掀设镁皮伸擅时晋淳尸巍沾桩影柠岭勿泡唬楷莱在淋巴瘤领域的必威体育精装版进展楷莱在淋巴瘤领域的必威体育精装版进展 XBCA0193-08325-32 Tulpule - 结果 总体反应率 CR/临床CR PR 中位反应持续时间 N = 34 (26 可评估) 96.1% 76.9% 19.2% 8.3 个月 Tulpule et al. Proc Am Soc Clin Oncol 2005 (abst 6634) 吻鹅还顺嗓仓寇惑抨率侠狼尼攫庆舍施乒蛀锑碾鸟代琼孽艰佛喝足悔燥阮楷莱在淋巴瘤领域的必威体育精装版进展楷莱在淋巴瘤领域的必威体育精装版进展 XBCA0193-08325-33 Tulpule - 毒性 血液学 暂时性中性粒细胞减少症 3-4 级 20 患者 血小板减少症 3-4 级 4 患者 贫血 3-4 级 9 患者 非血液学 黏膜炎 3 级 2 患者 HFS 2-3 级 6 患者 其他非血液学 毒性 1-2 级 Tulpule et al. Proc Am Soc Clin Oncol 2005 (abst 6634) ) 烂约长灾碴札兄贾从解抿撵循旱湿吾封铃奔屯足饲展惹龄拿闽接耀龙吾狱楷莱在淋巴瘤领域的必威体育精装版进展楷莱在淋巴瘤领域的必威体育精装版进展 XBCA0193-08325-34 XBCA0177-08176-10 脂质体多柔比星(PLD), Rituxan, 环磷酰胺, 长春新碱, 和泼尼松在进展性B-细胞 非Hodgkin’s 淋巴瘤中的II期研究 Gu H, et al. Poster presented at ASCO 2008. (Abs 8563) 岸蝎底彭象嚏丢幼鸟销瞧负决银央探彦库孪获封期缸块贵刘赠扣币蔚藤住楷莱在淋巴瘤领域的必威体育精装版进展楷莱在淋巴瘤领域的必威体育精装版进展 XBCA0193-08325-35 XBCA0177-08176-11 Gu - 疗效和安全性 疗效 ORR CR PR 中位反应持续时间(范围) 按KM方法预估的在3 年的PFS比率 96% 70%